Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Tech giants are pivoting to healthcare to clean up AI's image. Anthropic, Nvidia, Eli Lilly, and Google's Isomorphic Labs are pouring billions into drug discovery and medical AI — but breakthroughs are still years away. Meanwhile, concerns about cost, safety, and biosecurity risks loom large over the industry's healthcare ambitions.
AI's reputation is taking a hit — blamed for soaring energy bills, data center sprawl, and job losses. So what's the fix? Healthcare. Major AI players are making high-profile bets on medicine and drug discovery, hoping that saving lives will reshape how the public sees them.
Anthropic CEO Dario Amodei has signaled aggressive moves into biology and medicine ahead of the company's blockbuster IPO. Nvidia and Eli Lilly are jointly building a $1 billion AI-powered drug discovery lab in San Francisco, while Google's Isomorphic Labs raised $2.1 billion to expand its AI drug research collaborations with Novartis, Lilly, and J&J.
By the Numbers:
Why it matters: AI is already speeding up drug development and improving diagnostics — but it's also driving up healthcare costs and raising biosecurity concerns. For AI labs eyeing public trust and IPO valuations, healthcare represents both a genuine opportunity and a strategic move. The real test will be delivering tangible medical breakthroughs that patients and the public can actually feel.
